Vol. 18/No. 19

VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance associated with methylguanine methyltransferase (MGMT), is being investigated in patients with glioblastoma multiforme or gliosarcoma who had progressive disease during or after treatment with bevacizumab.

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

In its fight against pancreatic cancer, the Pancreatic Cancer Action Network aims to improve current survival and double survival by 2020.

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.

There is an urgent need for new approaches, particularly since pancreatic cancer is expected to become the second leading cause of cancer-related mortality by 2030.

Oncologists are well aware that by the time a new antineoplastic drug or regimen first enters the pages of a traditional reference textbook, the data supporting its use, including doses, schedules, and clinical indications, may already be considerably out-of-date.

Chimeric antigen receptor T-cell therapy for hematological malignancies took a huge step forward this summer with the FDA approval of Novartis